Get expert stock picks weekly from the Smart Investor Newsletter for smarter investments. GlaxoSmithKline's Nucala approval in China for treating CRSwNP showcases its leadership in addressing type 2 inflammation-related diseases, offering patients a non-surgical alternative to systemic corticosteroids and surgery.